Bavarian wants a more reliable, less cumbersome booster study

HERA, the EU’s new health preparedness unit, has made vaccines available for the biotech firm, enabling Bavarian to design a study where neither patient nor doctor knows what injection is being administered.

Photo: Finn Frandsen

Things will be less taxing when Bavarian Nordic initiates recruitment for a phase III trial of its Covid-19 vaccine candidate, ABNCoV2.

With support from European health authorities, the Danish biotech firm has been able to redesign its upcoming study to allow for a more direct comparison with the most widely used Covid-19 vaccine in Denmark, Pfizer/Biontech’s Comirnaty.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs